Home › Funds › B. Metzler seel. Sohn & Co. AG › VRTX

B. Metzler seel. Sohn & Co. AG position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

B. Metzler seel. Sohn & Co. AG reported holding 231,381 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$114.9M, representing 0.99% of its reported portfolio and ranking #22 among its reported holdings. B. Metzler seel. Sohn & Co. AG has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)231.38K sh
Reported value held$114.93M
Portfolio Weight0.99%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How B. Metzler seel. Sohn & Co. AG's VRTX position evolved

B. Metzler seel. Sohn & Co. AG first disclosed a stake in VRTX in Q3 2023 at 16,186 shares (US$5.6M). The position peaked in Q4 2025 at 515,269 shares, worth US$233.6M. Across 12 filings, B. Metzler seel. Sohn & Co. AG increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 231,381 shares valued at US$114.9M — a reduction of -279,655 shares quarter over quarter.. Notable position changes include a 127% increase in Q2 2024 (shares were roughly flat over the following quarter), a 102% increase in Q4 2024 (shares rose 20% over the following quarter), a 289% increase in Q1 2025 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 16.19K $5.63M New
Q4 2023 15.60K $6.35M Reduce
Q1 2024 15.54K $6.50M Hold
Q2 2024 35.23K $16.51M Add
Q3 2024 39.99K $18.60M Add
Q4 2024 80.76K $32.37M Add
Q1 2025 314.34K $152.40M Add
Q2 2025 319.62K $142.29M Add
Q3 2025 315.42K $123.53M Reduce
Q4 2025 515.27K $233.58M Add
Q1 2026 511.04K $228.20M Reduce
Q2 2026 231.38K $114.93M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has B. Metzler seel. Sohn & Co. AG held VRTX?

B. Metzler seel. Sohn & Co. AG has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is B. Metzler seel. Sohn & Co. AG's current position in VRTX?

As of Q2 2026, B. Metzler seel. Sohn & Co. AG holds 231.38K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $114.93M, representing 0.99% of its reported portfolio and ranking #22.

Has B. Metzler seel. Sohn & Co. AG been buying or selling VRTX?

In the latest 13F filing (Q2 2026), B. Metzler seel. Sohn & Co. AG reduced its position in VRTX. The position peaked in Q4 2025 at 515.27K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.